Transrectal ultrasound (TRUS) is a prostate imaging procedure in which a small ultrasound probe is placed in the rectum so sound waves can create real-time images of the prostate immediately in front of it. TRUS is especially useful for measuring prostate dimensions and volume, visualizing prostate anatomy during needle biopsy and providing the live ultrasound image used during many MRI-targeted procedures. Standard TRUS can show focal abnormalities, cysts, calcifications and changes in tissue appearance, but it cannot reliably diagnose or exclude prostate cancer by itself. Modern prostate-cancer detection therefore relies much more heavily on PSA-based risk assessment, MRI and biopsy pathology.
A prostate ultrasound answers primarily anatomical and procedural questions: How large is the prostate? What does its internal anatomy look like? Where is the needle during biopsy? It does not provide the same cancer-characterization information as prostate MRI. Standard TRUS is particularly valuable because it provides a real-time image while the prostate is being examined or sampled.
01What Is Transrectal Ultrasound and How Does a Prostate Ultrasound Work?
TRUS uses sound waves rather than radiation
Ultrasound creates images by sending high-frequency sound waves into tissue and measuring the echoes that return.
Different tissues return different amounts and patterns of sound.
The ultrasound system converts those echoes into a live grayscale image.
TRUS does not use:
- X-rays;
- CT radiation;
- or radioactive tracers.
Why is the ultrasound probe placed in the rectum?
The posterior surface of the prostate lies immediately in front of the rectum.
Placing the probe there brings the ultrasound transducer very close to the gland.
That short distance allows higher-resolution imaging than attempting to view the prostate only through the abdominal wall.
What happens during a diagnostic TRUS examination?
The exact workflow varies, but a typical examination involves:
- positioning the patient, commonly on the side or in another position suitable for rectal access;
- covering and lubricating the ultrasound probe;
- gently placing the probe into the rectum;
- obtaining axial and sagittal images of the prostate;
- measuring prostate dimensions;
- and reviewing any visible structural abnormalities.
A diagnostic ultrasound by itself generally does not require the same local anesthetic used for needle biopsy.
What does TRUS feel like?
Most men feel rectal pressure and temporary discomfort rather than severe pain.
Comfort can depend on:
- anal or rectal conditions;
- pelvic-floor tension;
- prostate tenderness;
- probe manipulation;
- and whether another procedure such as biopsy is being performed at the same time.
What structures can the urologist see?
Depending on image quality, TRUS can show:
- overall prostate outline;
- peripheral and central internal anatomy;
- transition-zone enlargement;
- the region of the urethra;
- seminal vesicles;
- cysts;
- calcifications;
- areas of altered echogenicity;
- and biopsy-needle position.
What does “hypoechoic” mean?
A hypoechoic area returns fewer ultrasound echoes and therefore appears darker than surrounding tissue.
Some prostate cancers can appear hypoechoic.
However, darkness on ultrasound is not specific for cancer.
Inflammation and benign prostate changes can also alter echogenicity.
Does a dark area on TRUS mean prostate cancer?
No.
This is an important historical change in prostate imaging.
Before widespread multiparametric MRI, visible hypoechoic ultrasound abnormalities were sometimes used to direct additional cores.
Modern evidence shows that standard grayscale TRUS is not reliable enough to detect or exclude prostate cancer on appearance alone.
TRUS is an ultrasound location tool, not a cancer verdict. A suspicious-looking area can be benign, and a clinically significant cancer can be difficult to distinguish on standard ultrasound. This is why contemporary evaluation places MRI and pathology ahead of grayscale TRUS for lesion characterization.
02How Does TRUS Measure Prostate Volume and Why Does Volume Matter?
Prostate volume is one of TRUS’s most useful measurements
The prostate is a three-dimensional gland.
A typical ultrasound volume assessment records:
- width on an axial image;
- anterior-posterior depth on an axial image;
- length on a sagittal image.
Those dimensions can then be used to estimate the gland’s volume.
How is prostate volume calculated?
A commonly used approximation treats the prostate as an ellipsoid:
Prostate volume ≈ width × height × length × 0.52.
When dimensions are measured in centimeters, the resulting volume is approximately expressed in milliliters or cubic centimeters.
For practical prostate assessment:
1 mL is approximately equivalent to 1 cc.
Why does prostate volume matter for PSA?
Prostate tissue itself produces PSA.
A larger benign gland can therefore produce more PSA than a small gland without cancer being present.
This is one reason a PSA value should not be interpreted in isolation.
How does TRUS contribute to PSA density?
PSA density is calculated as:
serum PSA ÷ prostate volume.
For example, the same PSA concentration can represent a very different density depending on whether the gland is:
- small;
- moderately enlarged;
- or very enlarged from BPH.
PSA density is now an important part of deciding how much concern remains after MRI.
Is TRUS volume exactly the same as MRI volume?
Not always.
TRUS and MRI can produce different volume estimates because:
- the imaging planes differ;
- the gland boundary may be interpreted differently;
- probe pressure can alter prostate geometry;
- and different ellipsoid or contouring methods may be used.
Current EAU diagnostic guidance recognizes this variation and notes that imaging-based prostate-volume methods are not perfectly standardized.
Which is more useful: DRE or imaging for prostate volume?
Imaging is more reproducible for volume calculation.
A digital rectal examination can identify whether a prostate feels enlarged, but it does not provide the same three-dimensional measurement required for a reliable PSA-density calculation.
What about transabdominal prostate ultrasound?
The prostate can also be estimated through an ultrasound probe placed on the lower abdomen.
That approach may be useful in urinary evaluation, particularly when bladder volume and post-void residual are also being measured.
However, transrectal ultrasound places the probe much closer to the gland and generally provides more detailed prostate anatomy.
Can TRUS show BPH?
Yes.
TRUS can demonstrate:
- overall gland enlargement;
- transition-zone enlargement;
- nodular internal architecture;
- and, in some men, protrusion of prostate tissue toward the bladder outlet.
Those findings can be useful when evaluating benign prostate enlargement, but structural enlargement does not automatically prove that BPH is causing a patient’s urinary symptoms.
Can TRUS show prostate calcifications?
Yes.
Calcifications are strongly reflective on ultrasound and may appear as bright echogenic foci, sometimes with acoustic shadowing.
Most are not evidence of prostate cancer.
Their clinical significance is discussed in Prostate Calcifications and Prostatic Stones.
Can TRUS show a cyst?
Yes.
Fluid usually has a characteristic dark or anechoic appearance on ultrasound.
TRUS can therefore identify:
- simple cystic structures;
- midline cysts;
- and selected fluid collections.
The importance depends on location, symptoms and surrounding findings.
Volume is not a cancer score. A large prostate can be entirely benign, and a small prostate can contain clinically significant cancer. Volume is useful because it provides context for PSA, urinary obstruction and procedure planning—not because large size itself tells whether cancer is present.
03How Is TRUS Used During Prostate Biopsy and MRI-Targeted Sampling?
Ultrasound lets the operator see the prostate and needle in real time
During many prostate biopsies, ultrasound functions as the procedural navigation system.
It can show:
- where the prostate begins and ends;
- the relationship of the gland to the rectum;
- the needle guide;
- the planned needle trajectory;
- and the needle entering prostate tissue.
Does “TRUS-guided biopsy” mean the needle goes through the rectum?
No.
This is one of the most important terminology distinctions.
A transperineal biopsy can still use a transrectal ultrasound probe for imaging.
In that case:
- the ultrasound probe is in the rectum;
- but the biopsy needle enters through the perineal skin.
By contrast, during a transrectal biopsy:
- the ultrasound probe is in the rectum;
- and the biopsy needle also crosses the rectal wall.
The difference between these needle routes is explained in Transperineal vs Transrectal Prostate Biopsy.
How does TRUS guide systematic biopsy?
Systematic biopsy samples predefined prostate regions rather than a specific MRI-visible target.
Ultrasound helps the operator:
- identify the prostate boundary;
- orient the base, mid-gland and apex;
- position cores within the intended peripheral regions;
- and avoid obvious non-prostate structures.
The tissue itself is then examined by pathology.
How does TRUS work with MRI-targeted biopsy?
MRI and ultrasound provide complementary information.
MRI is better at identifying and characterizing suspicious tissue.
Ultrasound is excellent for real-time procedural guidance.
During MRI-targeted prostate biopsy, the target seen on MRI can be transferred to the live TRUS image using:
- cognitive targeting;
- MRI-ultrasound software fusion;
- or another image-registration system.
What happens during MRI-ultrasound fusion?
The MRI was usually obtained before the biopsy.
During the biopsy:
- TRUS creates a live prostate image;
- software maps the prostate seen on MRI onto the prostate seen on ultrasound;
- the MRI lesion is displayed as a target;
- the needle path is planned through that region;
- and tissue cores are obtained for pathology.
Can TRUS alone target a visible prostate abnormality?
Technically yes, but standard ultrasound-visible abnormalities are not sufficiently specific to serve as the modern primary cancer-detection strategy.
Current EAU guidance states that the diagnostic yield of adding cores simply because an area looks hypoechoic on standard TRUS is negligible.
MRI-directed targeting has therefore become much more important.
What does ultrasound contribute when MRI already found the lesion?
MRI and TRUS solve different problems.
MRI provides:
- better lesion characterization;
- PI-RADS assessment;
- anatomical localization;
- and information about possible local extension.
TRUS provides:
- live visualization;
- prostate orientation during the procedure;
- needle tracking;
- rapid volume measurement;
- and a platform for MRI-ultrasound registration.
Does ultrasound determine whether the biopsy core contains cancer?
No.
After tissue is removed, a pathologist examines the sample under a microscope.
If prostate cancer is present, pathology—not ultrasound—determines:
- histological type;
- Gleason patterns;
- ISUP Grade Group;
- and the amount of cancer in the sampled tissue.
The biopsy process itself is explained in What Is a Prostate Biopsy?.
Does TRUS change biopsy recovery?
The ultrasound probe itself is usually not the major driver of post-biopsy recovery.
Recovery is influenced more by:
- needle route;
- number and distribution of cores;
- local anesthesia;
- bleeding tendency;
- prostate size;
- baseline urinary symptoms;
- and infection exposure.
For expected bleeding, urinary symptoms and warning signs after tissue sampling, see Prostate Biopsy Recovery.
TRUS is often the “eyes” of the biopsy procedure, but pathology provides the diagnosis. This distinction prevents an ultrasound image, an MRI lesion and a cancer diagnosis from being treated as interchangeable findings.
04Can TRUS Detect Prostate Cancer, and How Does It Differ From MRI?
Standard TRUS is not reliable enough to rule cancer in or out
Some prostate cancers create ultrasound changes.
Others do not.
Benign tissue can also look abnormal.
For that reason, current EAU prostate-cancer guidance states directly that standard TRUS is not reliable for detecting prostate cancer.
Why can ultrasound miss cancer?
Cancer may:
- have similar echogenicity to normal tissue;
- be too small to produce a visible difference;
- sit within heterogeneous BPH tissue;
- be obscured by calcification or artifact;
- or occupy an anatomical location that is difficult to distinguish on grayscale imaging.
Why can ultrasound produce a false alarm?
Non-cancer conditions can change prostate echogenicity.
Examples include:
- prostatitis;
- BPH nodules;
- fibrosis;
- calcification;
- cysts;
- previous biopsy changes;
- and hemorrhage.
A focal ultrasound abnormality therefore requires clinical context rather than being labeled cancer from the image alone.
Is TRUS used to stage prostate cancer?
Its role in local cancer staging is limited.
Standard TRUS is not sufficiently accurate for confidently determining:
- microscopic extension through the prostate capsule;
- seminal-vesicle invasion;
- or the complete local extent of a tumor.
MRI provides substantially more useful soft-tissue information for modern local assessment.
Does TRUS show lymph-node spread?
No.
Routine prostate TRUS is not an appropriate examination for excluding pelvic lymph-node metastases.
When staging imaging is necessary, the test is selected according to cancer risk and clinical setting rather than using prostate ultrasound as a whole-body staging method.
Is prostate MRI better than TRUS?
That depends on the question.
For characterizing suspicious prostate lesions, MRI is substantially more informative.
For real-time needle visualization during biopsy, ultrasound has a major practical advantage.
For quick prostate-volume measurement, TRUS remains useful.
The tests are therefore often complementary rather than interchangeable.
Can TRUS replace MRI before prostate biopsy?
Not in the standard modern diagnostic pathway for a man with suspected organ-confined prostate cancer.
Current EAU guidance recommends MRI before prostate biopsy in that setting.
TRUS remains important because the biopsy itself is commonly ultrasound-guided after the MRI has already identified where suspicion is highest.
Can TRUS replace PSA?
No.
PSA testing provides biochemical information that ultrasound cannot.
The two tests answer different questions.
PSA helps estimate cancer probability, while ultrasound helps describe anatomy and support procedures.
Can a normal TRUS rule out prostate cancer?
No.
A normal-looking grayscale ultrasound should not be used as reassurance that clinically significant cancer is absent when:
- PSA remains concerning;
- PSA density is elevated;
- DRE is suspicious;
- MRI shows an abnormal lesion;
- or hereditary risk is substantial.
Can an abnormal TRUS confirm prostate cancer?
No.
A hypoechoic, irregular or otherwise unusual ultrasound finding can raise interest, but a cancer diagnosis requires the broader diagnostic process.
That process is organized in How Prostate Cancer Is Diagnosed.
Where does TRUS fit after a positive biopsy?
Once pathology confirms prostate cancer, the most important descriptors shift toward:
- PSA;
- Gleason patterns;
- ISUP Grade Group;
- tumor extent;
- clinical stage;
- and appropriate staging imaging.
TRUS may still be useful for selected procedures, but it does not replace formal cancer grading or staging.
Do not interpret a “normal prostate ultrasound” as a negative cancer test. Standard TRUS can miss clinically significant disease. Persistent PSA, DRE or MRI concern should be evaluated according to the complete prostate-cancer diagnostic pathway rather than stopped by a reassuring grayscale ultrasound appearance.
→TRUS, MRI, PSA and Biopsy: What Each Test Actually Tells You
| Test | Main information | Useful for | Cannot reliably establish by itself |
|---|---|---|---|
| TRUS | Real-time prostate anatomy and dimensions. | Volume measurement, procedural visualization, biopsy guidance. | Whether a visible abnormality is prostate cancer. |
| Prostate MRI | Tissue characteristics and lesion localization. | PI-RADS assessment, MRI targets, local anatomical evaluation. | Definitive microscopic cancer diagnosis or Grade Group. |
| PSA | Concentration of prostate-specific antigen in blood. | Risk assessment, follow-up and calculation of PSA density. | Whether an elevated value is caused by cancer. |
| PSA density | PSA relative to prostate volume. | Refining cancer probability, especially with MRI findings. | Cancer diagnosis. |
| DRE | Palpable consistency and posterior prostate abnormalities. | Detecting nodules, induration, asymmetry or fixation. | Microscopic pathology. |
| MRI-targeted biopsy | Tissue from a specific MRI-defined target. | Confirming whether suspicious MRI tissue contains cancer. | Whether unsampled parts of the prostate are completely cancer-free. |
| Biopsy pathology | Microscopic tissue architecture. | Cancer diagnosis, Gleason patterns, ISUP Grade Group. | Whole-body metastatic staging. |
?Common Questions About Prostate Ultrasound and TRUS
| Question | Practical answer |
|---|---|
| What is TRUS? | Transrectal ultrasound is a procedure in which an ultrasound probe is placed in the rectum to create real-time images of the nearby prostate. |
| Is TRUS the same as prostate ultrasound? | TRUS is one type of prostate ultrasound and is commonly used when detailed prostate imaging or biopsy guidance is needed. |
| Does TRUS use radiation? | No. It uses high-frequency sound waves. |
| Why is the probe inserted into the rectum? | The rectum lies directly behind the prostate, allowing the transducer to image the gland from very close range. |
| Is TRUS painful? | A diagnostic examination usually causes pressure or temporary discomfort rather than severe pain, although individual experience varies. |
| Does TRUS require anesthesia? | Diagnostic TRUS usually does not require the same local anesthesia used when needle biopsy is performed. |
| What can TRUS measure? | Prostate width, anterior-posterior depth and length can be measured to estimate volume. |
| How is prostate volume calculated? | A common approximation is width × depth × length × 0.52. |
| Why does prostate volume matter? | It helps interpret BPH, plan procedures and calculate PSA density. |
| Can TRUS calculate PSA density? | TRUS supplies the prostate-volume estimate; PSA density is then calculated by dividing blood PSA by that volume. |
| Can TRUS diagnose prostate cancer? | No. Standard TRUS is not sufficiently reliable or specific for cancer diagnosis. |
| Can prostate cancer appear dark on TRUS? | Yes, some cancers are hypoechoic, but many benign abnormalities can also appear dark and some cancers are not visibly different. |
| Can a normal TRUS rule out prostate cancer? | No. |
| Can TRUS see BPH? | Yes. It can show prostate enlargement and nodular transition-zone anatomy. |
| Can TRUS see prostate calcifications? | Yes. Calcifications often appear very bright on ultrasound. |
| Can TRUS show cysts? | Yes. Fluid-filled structures can often be distinguished from solid prostate tissue. |
| Is TRUS better than MRI for prostate cancer? | Not for lesion characterization. MRI provides much stronger tissue characterization, while TRUS is particularly useful for live biopsy guidance and volume measurement. |
| Does MRI replace TRUS during biopsy? | Usually not. Many MRI-targeted biopsies still use TRUS as the real-time procedural image. |
| What is MRI-ultrasound fusion? | Software aligns a prior MRI target with the live prostate image obtained by ultrasound during biopsy. |
| Does TRUS-guided biopsy mean transrectal biopsy? | No. A transperineal biopsy can use a transrectal ultrasound probe while the needle enters through perineal skin. |
| Can TRUS guide transperineal biopsy? | Yes. This is common in modern practice. |
| Can TRUS guide transrectal biopsy? | Yes. |
| What confirms cancer after TRUS-guided biopsy? | A pathologist examines the tissue cores under a microscope. |
| Can TRUS determine Gleason score? | No. Gleason patterns and ISUP Grade Group are determined from biopsy pathology. |
| Can TRUS stage prostate cancer? | Standard TRUS has limited accuracy for local staging and is not a substitute for appropriate MRI or other staging evaluation. |
| Can TRUS detect lymph-node metastases? | Routine prostate TRUS is not used to reliably exclude lymph-node spread. |
| Is TRUS useful after a high PSA? | It can provide prostate volume and procedural guidance, but modern cancer evaluation usually integrates PSA with MRI and biopsy risk assessment rather than using TRUS appearance alone. |
ΣKey Clinical Takeaways
- TRUS means transrectal ultrasound.
- A small ultrasound probe is placed in the rectum immediately behind the prostate.
- TRUS uses sound waves rather than ionizing radiation.
- The procedure provides live grayscale images of prostate anatomy.
- TRUS is particularly useful for prostate measurement and biopsy guidance.
- Prostate width, depth and length can be used to estimate gland volume.
- A common volume formula is width × depth × length × 0.52.
- Imaging-derived prostate volume is an estimate rather than a direct measurement of every contour.
- Prostate volume helps interpret PSA.
- PSA density is serum PSA divided by prostate volume.
- The same PSA value can have different significance in a small prostate and a markedly enlarged prostate.
- TRUS and MRI volume estimates can differ.
- DRE is less precise than imaging for calculation of prostate volume.
- TRUS can show benign prostate enlargement.
- TRUS can identify calcifications and cystic structures.
- Some prostate cancers appear hypoechoic on ultrasound.
- A hypoechoic lesion is not synonymous with cancer.
- Inflammation, BPH and other benign conditions can create abnormal ultrasound appearances.
- Standard TRUS is not reliable enough to detect or exclude prostate cancer by appearance alone.
- A normal TRUS cannot rule out clinically significant cancer.
- TRUS has limited accuracy for local prostate-cancer staging.
- MRI is more informative for suspicious lesion characterization.
- TRUS remains highly useful as a live procedural imaging system.
- Modern MRI-targeted biopsy frequently combines prior MRI with real-time ultrasound.
- MRI-ultrasound fusion transfers an MRI lesion coordinate onto the live TRUS image.
- TRUS can guide both transperineal and transrectal biopsy.
- The location of the ultrasound probe does not determine the biopsy needle route.
- A transrectal ultrasound probe may guide a transperineal biopsy needle entering through the skin.
- Systematic biopsy can also be performed under TRUS guidance.
- Ultrasound can show the biopsy needle in relation to prostate anatomy.
- Pathology—not ultrasound—confirms prostate cancer.
- Pathology determines Gleason patterns and ISUP Grade Group.
- TRUS, MRI, PSA and biopsy should therefore be understood as complementary rather than interchangeable diagnostic tools.
Clinical bottom line: transrectal ultrasound is best understood as a real-time prostate anatomy and procedure-guidance tool. It can measure the gland, estimate prostate volume, support PSA-density calculation, identify structural changes and show a biopsy needle as tissue is sampled. What it cannot reliably do is look at a grayscale abnormality and determine whether it is cancer. In the modern diagnostic pathway, MRI does most of the lesion characterization, TRUS often provides the live procedural image, and biopsy pathology establishes whether cancer is actually present and how it is graded.
Medical disclaimer: This article provides general medical education about prostate ultrasound and TRUS. Whether ultrasound, MRI or biopsy is appropriate depends on PSA, PSA density, digital rectal examination, urinary symptoms, previous biopsy history, family/genetic risk and the clinical reason for imaging. A normal ultrasound should not be used independently to exclude prostate cancer.
For the complete sequence from cancer suspicion to tissue diagnosis, see How Prostate Cancer Is Diagnosed. For the blood test that commonly starts the diagnostic pathway, see PSA Testing and PSA Density. For imaging that characterizes suspicious tissue, review What Is a Prostate MRI?, Multiparametric Prostate MRI, PI-RADS Scoring and What Is a Prostate Lesion?. If ultrasound is being used during tissue sampling, continue with What Is a Prostate Biopsy?, Transperineal vs Transrectal Prostate Biopsy and MRI-Targeted Prostate Biopsy. For expected symptoms after tissue sampling, see Prostate Biopsy Recovery. For the broader disease pathway, return to the Prostate Cancer hub. The next guide explains Gleason score and Grade Groups, including how biopsy pathology grades prostate cancer from Gleason 3+3 through Gleason 9–10.
Evidence Sources
- European Association of Urology — Prostate Cancer Diagnostic Evaluation: standard TRUS limitations, prostate-volume estimation, PSA density, MRI before biopsy, ultrasound-guided biopsy and local-staging limitations.
- National Cancer Institute — Prostate Cancer Treatment PDQ: definition of transrectal ultrasound and its use during prostate biopsy.
- National Cancer Institute — Prostate Cancer Treatment, Health Professional Version: TRUS biopsy guidance and limitations for assessment of local tumor extension.
- National Cancer Institute — PSA Test Fact Sheet: PSA evaluation, ultrasound-guided transperineal and transrectal biopsy and the limitation of ultrasound alone for prostate-cancer diagnosis.
- American Urological Association / Society of Urologic Oncology — Early Detection of Prostate Cancer: MRI-directed biopsy, ultrasound guidance and contemporary prostate-cancer diagnostic pathways.
